Impact of concurrent colonic CMV infection on clinical outcomes in immune checkpoint inhibitor–induced colitis
European Journal of Cancer · 2026-07 · 243 · 116795
DOI: 10.1016/j.ejca.2026.116795 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-07. Verfasst von Hajir Ibraheim und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Digestion and Reproduction, Imperial College London, UK; Department of Cancer Services, The Royal Marsden Hospital, UK. Ele…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Immune Checkpoint Inhibitors, Colitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Leona M. and Harry B. Helmsley Charitable Trust, National Institute for Health Research Imperial Biomedical Research Centre.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICI) frequently trigger ICI-colitis, commonly leading to ICI discontinuation. With expanding ICI use, ICI-colitis is emerging as a significant clinical challenge. Cytomegalovirus (CMV) infection is known to occur in ICI-colitis, but its prevalence, risk factors and clinical impact are poorly defined. This study aimed to characterise the clinical trajectory of ICI-colitis patients with concurrent colonic CMV infection as compared to a CMV-negative colitis group. METHODS: We retrospectively analysed consecutive ICI-treated patients with endoscopically and/or histologically confirmed ICI-colitis at two UK hospitals between 2015 and 2024. Clinical, endoscopic (Mayo Endoscopic Score, MES), treatment and oncologic outcome data were collected. CMV was identified by immunohistochemistry (IHC) on colonic biopsies. CMV-positive colitis cases were compared with CMV-negative colitis using chi- squared, Mann-Whitney U, and multivariable regression analyses. RESULTS: Among 249 ICI-colitis patients, IHC proven CMV-positive colitis was detected in 21 (8.4%). CMV-positive colitis was associated with dual ICI therapy (OR 2.8, CI 1.06-7.15), prior infliximab exposure (OR 6.4, CI 2.56-16.7), bloody stool (OR 2.7, CI 1.05-6.69), and higher endoscopic severity (MES 2-3; OR 4.1, CI 1.60-10.38), despite similar CTCAE diarrhoea grades between groups. They also had a higher likelihood of requiring escalation to advanced therapy (80% vs 41.5%; OR 5.6, CI 1.96-15.74), with this association remaining significant after adjusting for endoscopic severity (p = 0.049). Colectomy rates were higher albeit low overall. Antiviral therapy did not significantly affect corticosteroid duration or recurrence, and CMV tissue status did not influence overall or progression-free survival. CONCLUSION: Concurrent CMV-positive colitis occurs in a notable subset of ICI-colitis patients and may worsen disease severity, highlighting the importance of endoscopic biopsy, especially in steroid-refractory cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Metabolism, Digestion and Reproduction, Imperial College London, UK; Department of Cancer Services, The Royal Marsden Hospital, UK. Electronic address: h.ibraheim@nhs.net.
- Department of Cancer Services, The Royal Marsden Hospital, UK. Electronic address: paolo.d'arienzo@nhs.net.
- Department of Cancer Services, The Royal Marsden Hospital, UK. Electronic address: nathan.dean@nhs.net.
- Department of Cancer Services, The Royal Marsden Hospital, UK. Electronic address: w.duggleby@nhs.net.
- Department of Cancer Services, The Royal Marsden Hospital, UK. Electronic address: ashish.singh@rmh.nhs.uk.
- Department of Cancer Services, The Royal Marsden Hospital, UK. Electronic address: thubeena.manickavasagar@rmh.nhs.uk.
Förderung
- Wellcome Trust
- Leona M. and Harry B. Helmsley Charitable Trust
- National Institute for Health Research Imperial Biomedical Research Centre
- Imperial College London
- National Institute for Health and Care Research
- Imperial College Healthcare NHS Trust
Zitieren
APA
Ibraheim, H., d'Arienzo, P. D., Dean, N. J., Duggleby, W., Singh, A., Manickavasagar, T., Kalofonou, F., Aboulela, M., Vadera, S., Anderson, K. E., Campbell, M., Lewis, J., Muehlschlegel, P., Mullings, S., Symington, J. J., Dar, S., Oommen, I., Hafidh, J. S., Goldin, R., …, & Powell, N. (2026). Impact of concurrent colonic CMV infection on clinical outcomes in immune checkpoint inhibitor–induced colitis. European Journal of Cancer, 243, 116795. https://doi.org/10.1016/j.ejca.2026.116795
Vancouver
Ibraheim H, d'Arienzo PD, Dean NJ, Duggleby W, Singh A, Manickavasagar T, et al. Impact of concurrent colonic CMV infection on clinical outcomes in immune checkpoint inhibitor–induced colitis. European Journal of Cancer. 2026;243:116795. doi:10.1016/j.ejca.2026.116795
BibTeX
@article{Ibraheim2026,
author = {Ibraheim, Hajir and d'Arienzo, Paolo Davide and Dean, Nathan James and Duggleby, William and Singh, Ashish and Manickavasagar, Thubeena and Kalofonou, Foteini and Aboulela, Mohamed and Vadera, Sree and Anderson, Kirsty Ellen and Campbell, Michael and Lewis, Jacob and Muehlschlegel, Paula and Mullings, Stephanie and Symington, Jake James and Dar, Sabeera and Oommen, Irene and Hafidh, Jenna Saad and Goldin, Robert and Alexander, James and Olsson-Brown, Anna Clare and Young, Kate and Powell, Nicholas},
title = {Impact of concurrent colonic CMV infection on clinical outcomes in immune checkpoint inhibitor–induced colitis},
journal = {European Journal of Cancer},
year = {2026},
volume = {243},
pages = {116795},
doi = {10.1016/j.ejca.2026.116795}
}
EUVIMED